Funder
national institutes of health
division of cancer epidemiology and genetics, national cancer institute
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology
Reference41 articles.
1. Papac R, Galton D, Till M, Wiltshaw E. Preliminary clinical trial of p-di-2-chloroethyl-amino-L-phenylalanine (CB 3025, melphalan) and of di-2-chloroethyl methanesulfonate (CB 1506). Ann N Y Acad Sci. 1958;68:1126–7.
2. Barlogie B, Shaughnessy J, Tricot G, et al. Treatment of multiple myeloma. Blood. 2016;103:20–33.
3. Verhoef C, Wilt JHW, Grünhagen DJ, Geel AN, Hagen TLM, Eggermont AMM. Isolated limb perfusion with melphalan and TNF-α in the treatment of extremity sarcoma. Curr Treat Options Oncol. 2007;8:417–27.
4. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol. 1995;13:1786–99.
5. Hsieh T, Liao A, Francis JH, et al. Comparison of efficacy and toxicity of intravitreal melphalan formulations for retinoblastoma. PLoS ONE. 2020;15:4–11.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献